A California jury has awarded $40 million in damages to two women who claimed that long-term use of Johnson & Johnson’s talc-based baby powder caused their ovarian cancer, marking a significant development in the company’s ongoing talc litigation. The verdict was delivered Friday in Los Angeles Superior Court, where jurors concluded that Johnson & Johnson knew for decades about potential cancer risks associated with its baby powder products but failed to warn consumers.
The jury awarded $18 million to Monica Kent and $22 million to Deborah Schultz and her husband. Both women are California residents who testified that they used Johnson & Johnson baby powder daily after bathing for roughly 40 years. Kent was diagnosed with ovarian cancer in 2014, while Schultz received her diagnosis in 2018. According to trial testimony, both women underwent extensive medical treatment, including major surgeries and numerous rounds of chemotherapy.
During closing arguments, plaintiffs’ attorney Andy Birchfield told jurors that internal company knowledge about cancer risks linked to talc dated back to the 1960s. He argued that Johnson & Johnson deliberately concealed this information to protect sales. The jury ultimately agreed, finding the company liable for failing to warn consumers about potential dangers.
Johnson & Johnson has strongly denied the claims and announced plans to immediately appeal the verdict. Erik Haas, the company’s worldwide vice president of litigation, said the company expects to prevail, arguing that the decision represents an “aberrant adverse verdict.” Defense attorney Allison Brown told jurors that no major U.S. health authority has established a causal link between talc use and ovarian cancer, and that no scientific study proves talc can migrate to reproductive organs.
Johnson & Johnson is currently facing more than 67,000 lawsuits related to its talc products, the majority involving ovarian cancer claims. The company stopped selling talc-based baby powder in the United States in 2020, switching to a cornstarch alternative. Efforts to resolve the litigation through bankruptcy have been rejected multiple times by federal courts, allowing cases to resume.
The verdict underscores the ongoing legal and financial risks Johnson & Johnson faces as talc cancer lawsuits continue to move forward in courts across the country.


Dell Stock Hits Record High After Trump Endorsement, AI Server Demand Fuels Rally
Aung San Suu Kyi Moved to House Arrest Amid Myanmar Political Crisis
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Bolsonaro Discharged After Shoulder Surgery Amid Ongoing Legal Troubles
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations
CSL Shares Crash as Profit Warning and $5 Billion Impairment Shake Investors
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting
Ibiden Stock Surges as AI Chip Demand Boosts Profit Outlook
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident
Arcadia Mayor Eileen Wang Pleads Guilty in China Foreign Agent Case
Federal Appeals Court Allows Texas SB4 Immigration Law Enforcement to Proceed
Trump-Xi Summit Sparks Renewed Hope for Americans Detained in China 



